The Medicines Discovery Catapult has launched 22 partnerships with UK contract research organisations as it formalises its relationship with an increasingly important part of the country’s life sciences sector.
Contract research organisations, which provide outsourced support for pharmaceutical industry drug development, have been growing in number for years. But previously the catapult engaged only in ad hoc partnerships with such companies.
On the 26 April the catapult announced the 22 CROs that will join its Virtual R&D Discovery Services platform. It said it would help to match them with small and medium-sized enterprises looking for the specific expertise that they provide. This announcement marks the formalisation of the catapult’s work with CROs.